Valine

Valine

SCHEMBL7689739

CC(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)O.CC(C)[C@H](N)C(=O)O

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.51
ITGB3 P05106 1/20 0.50
ITGA2B P08514 1/20 0.50
CA2 P00918 1/20 0.50
LMNA P02545 1/20 0.50
ACE P12821 4/20 0.49
MME P08473 4/20 0.48
CPA1 P15085 3/20 0.47
ACE2 Q9BYF1 3/20 0.47
GPR34 Q9UPC5 1/20 0.45
GNPAT O15228 1/20 0.44
FOLH1 Q04609 2/20 0.44
MAPK1 P28482 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL504108 0.89 ALDH1A1 (0.61) ALDH1A1ITGB3ITGA2BCA2LMNA
SCHEMBL27547070 0.89 ALDH1A1 (0.61) ALDH1A1ITGB3ITGA2BCA2LMNA
SCHEMBL5996017 0.89 ALDH1A1 (0.61) ALDH1A1ITGB3ITGA2BCA2LMNA
Acetyl Tyrosine SCHEMBL7688897 0.88 FOLH1 (0.58) ITGB3ITGA2BCA2LMNAACE
Afalanine SCHEMBL7691017 0.88 GNPAT (0.56) ITGB3ITGA2BACEMMECPA1
SCHEMBL22503652 0.86 MME (0.56) ALDH1A1CA2ACEMMECPA1
SCHEMBL22503794 0.86 MME (0.56) ALDH1A1CA2ACEMMECPA1
SCHEMBL23030208 0.81 MME (0.58) ALDH1A1CA2ACEMMECPA1
SCHEMBL20540755 0.81 MME (0.58) ALDH1A1CA2ACEMMECPA1
SCHEMBL20540509 0.81 MME (0.58) ALDH1A1CA2ACEMMECPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002068586-A2 HIV/FIV PROTEASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2002-09-06 WO claimed
WO-2002068586-A2 HIV/FIV PROTEASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2002-09-06 WO disclosed